We achieved important clinical, operational and commercial corporate objectives during the quarter. We reported topline results from the CLOVER-WaM pivotal study in WM and look forward to filing our NDA submission with a request for accelerated regulatory approval in the coming months, said James Caruso, president and CEO of Cellectar Biosciences (CLRB). In addition to our lead iopofosine I 131 program, we plan to further advance the value of our phospholipid radioconjugate pipeline and are preparing alpha and Auger PRCs for initiation of solid tumor clinical studies as business conditions allow.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- Options Volatility and Implied Earnings Moves Today, November 18, 2024
- Cellectar Biosciences signs strategic supply agreement with NorthStar
- Cellectar, SpectronRx sign agreement to manufacture iopofosine I 131
- CLRB Upcoming Earnings Report: What to Expect?
- Cellectar Biosciences regains compliance with Nasdaq